Colorectal Cancer – Epidemiology – Asia-Pacific

Clarivate Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of colorectal cancer for each country as well as annualized case counts projected to the national population.

In addition to forecasting diagnosed incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s colorectal cancer forecast will answer the following questions:

  • How will change in the levels of exposure to known risk or protective factors affect the number of people diagnosed with colorectal cancer per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with colorectal cancer per year?
  • How will improvements in survival change the number of people living with a diagnosis of colorectal cancer?
  • How will the decreasing recurrence risk change the number of first-line drug-treatment opportunities for colorectal cancer?
  • How will the epidemiology of colorectal cancer be impacted in the countries with colorectal cancer screening programs?
  • Of all people diagnosed with colorectal cancer, how many in each country across developed countries are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of colorectal cancer over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following colorectal cancer subpopulations:

  • Diagnosed incident cases of colon cancer by stage at diagnosis.
  • Diagnosed incident cases of rectal cancer by stage at diagnosis.
  • Diagnosed prevalent cases of colon cancer by drug-treatment status.
  • Diagnosed prevalent cases of rectal cancer by drug-treatment status.
  • First-line drug-treatable colorectal cancer population (mutated BRAF) by treatment status.
  • First-line drug-treatable colorectal cancer population (mutated RAS) by treatment status.
  • First-line drug-treatable colorectal cancer population (wild-type RAS/BRAF) by treatment status.
  • Second-line drug-treatable colorectal cancer population (mutated BRAF) by treatment status.
  • Second-line drug-treatable colorectal cancer population (mutated RAS) by treatment status.
  • Second-line drug-treatable colorectal cancer population (wild-type RAS/BRAF) by treatment status.
  • … and many more (details available on request).

Note: Coverage may vary by country.